8-K

================================================================================


                United States Securities and Exchange Commission
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                         Date of Report: April 2, 2007
                -----------------------------------------------
               (Date of earliest event reported: March 19, 2007)

                              ONCOLOGIX TECH INC.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)

            Nevada                001-15482                      86-1006416
 ---------------------------      ----------                  -----------------
(State or other jurisdiction     (Commission                 (IRS Employer
     of incorporation)           File Number)                Identification No.)

                     2850 Thornhills Ave., S.E., Suite 104
                          Grand Rapids, Michigan 49546
               -------------------------------------------------
              (Address of principal executive offices) (Zip Code)

                                 (616) 977-9933
                         -----------------------------
                        (Registrant's telephone number)


Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)


[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)


[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))




Unless otherwise indicated or the context otherwise requires, all references
below in this report on Form 8-K to "we," "us" and the "Company" are to
Oncologix Tech Inc., a Nevada corporation

Cautionary Note Regarding Forward-looking Statements and Risk Factors

The Registrant's Form 10-KSB, any Form 10-QSB or any Form 8-K of the Registrant
or any other written or oral statements made by or on behalf of the Registrant
may contain forward-looking statements which reflect the Registrant's current
views with respect to future events and financial performance. The words
"believe," "expect," "anticipate," "intends," "estimate," "forecast," "project,"
and similar expressions identify forward-looking statements. All statements
other than statements of historical fact are statements that could be deemed
forward-looking statements, including any statements of the plans, strategies
and objectives of management for future operations; any statements concerning
proposed new products, services, developments or industry rankings; any
statements regarding future economic conditions or performance; any statements
of belief; any statements regarding the validity of our intellectual property
and patent protection; and any statements of assumptions underlying any of the
foregoing. Such "forward-looking statements" are subject to risks and
uncertainties set forth from time to time in the Registrant's SEC reports and
include, among others, the Risk Factors described below.

Readers are cautioned not to place undue reliance on such forward-looking
statements as they speak only of the Registrant's views as of the date the
statement was made. The Registrant undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Item 2.01 Completion of Acquisition or Disposition of Assets.

As previously reported, on January 8, 2007, Oncologix Tech Inc., (formerly
BestNet Communications Corp.), a Nevada corporation (the "Seller") entered into
an Asset Purchase Agreement with Interactive Media Technologies, Inc., a Florida
corporation (the "Buyer"), to sell most of the assets, including the goodwill,
of our Telephone Business. The purchase price for purchased assets and assumed
liabilities is $60,000 payable as follows: (i) $30,000 payable upon the
execution of the Asset Purchase Agreement; and (ii) $30,000 payable upon the
Closing Date of February 15, 2007. On the closing date, the Buyer also agrees to
reimburse the Seller for all expenses paid by the Seller after January 31, 2007
(the "Switchover Date") through the Closing Date which relate to liabilities
associated with the business that were incurred by the Seller after the
Switchover Date.

On January 12, 2006, we file a Current Report on Form 8-K (the "8-K Report") to
report this transaction. We amended that Current Report on Form 8-K/A, on
January 18, 2007 to provide the pro forma financial information required by Item
9.01(b).

In March 2007, we received the final "Closing Date" payment of $30,000 and have
reconciled all outstanding liabilities with respect to the sale of the Telephone
Business.

Item 8.01  Other Events

In March 2007, the Company's subsidiary, Oncologix Corporation, entered into a
Research Agreement with Institute De Cardiologie De Montreal ("ICM") to complete
a Microsphere Rabbit Study. Under this study, ICM and Dr. Raoul Bonan have
agreed to provide the facilities, equipment, and expertise necessary to assist
Oncologix in performing animal research studies with its Oncosphere System. The
studies are required to be completed as part of the data submitted to the Food
and Drug Administration (FDA) to support a request for initiation of human
clinical research. Total estimated costs for this study are expected to be
approximately $30,000.





ITEM 9.01 Financial Statements and Exhibits

(a) Exhibits

Exhibit             Title
- -------             -----

  99                Press release, issued by BestNet Communications Corp. Dated
                    March 19, 2007




                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            BestNet Communications Corporation


                                            By:  /s/  Stanley L. Schloz
                                               --------------------------------
                                                      Stanley L. Schloz
                                                      President

                                            By:  /s/  Michael A. Kramarz
                                               --------------------------------
                                                      Michael A. Kramarz
                                                      Chief Financial Officer




     Date: April 2, 2007

EX-99

                                                                      EXHIBIT 99

ONCOLOGIX TECH INC. ANNOUNCES SITE SELECTION AND INITIATION OF PRE-CLINICAL

(ANIMAL) TESTING OF THE ONCOSPHERE SYSTEM


GRAND RAPIDS, Mich.--(Marketwire) March 19, 2007 - Oncologix Tech Inc.'s (OTC
BB: OCLG.OB) wholly owned subsidiary Oncologix Corporation announced today that
the Institut de Cardiologie de Montreal (Montreal Heart Institute) and Dr. Raoul
Bonan have agreed to provide the facilities, equipment, and expertise necessary
to assist Oncologix in performing animal research studies with its Oncosphere
System. The studies are required to be completed as part of the data submitted
to the Food and Drug Administration (FDA) to support a request for initiation of
human clinical research.

One of Montreal Heart Institute's (MHI) primary missions is to develop and run
research and technology development programs related to their expertise in
vascular interventions. Given the reputation they have earned in basic and
clinical research, they often work with private businesses such as Oncologix. In
addition to their expertise in vascular interventions, Dr. Bonan and MHI have
teamed with industry in the development of interventional radiation based
treatments such as vascular brachytherapy and brachytherapy for atrial flutter
and fibrillation, which makes them a uniquely qualified location to conduct
animal studies with the Oncosphere System.

The first of two animal studies is scheduled to begin in March and both studies
should be completed by the end of 2007 for inclusion in an Investigational
Device Exemption (IDE) to the FDA requesting approval to begin human trials.
Accomplishing these goals continues to keep Oncologix on track with its plan to
initiate clinical trials with the Oncosphere System in early 2008 and to gain
commercial approval by the end of 2009.

According to Adam Lowe, President and COO of Oncologix, "We are extremely
pleased to working with Dr. Bonan and the Montreal Heart Institute. We have been
fortunate to align ourselves with individuals and organizations like these with
a long history of successful medical research and technology development."



In addition Stanley L. Schloz, Oncologix Tech Inc.'s Chief Executive Officer,
stated "The asset sale of the BestNet phone business to Interactive Media
Technologies, Inc was completed March 19, 2007. The company will now focus all
of it's energy and resources on it's medical subsidiary, Oncologix Corporation."




About Oncologix Tech Inc. and Oncologix Corp.:
- ----------------------------------------------

Oncologix Tech Inc., (formerly BestNet Communications Corp.) was formerly a
provider of long distance telephone communication services. On January 2007, the
Company entered into an agreement to dispose of the telephone business.

Oncologix Corporation, based in Atlanta GA, is a wholly owned subsidiary of
Oncologix Tech Inc. Oncologix is developing an advanced medical treatments for
soft tissue cancers; the Oncosphere System. The Oncosphere System is a
brachytherapy (radiation therapy) device being developed for the treatment of
soft tissue cancers. It is based on a radioactive micro-particle designed to
deliver therapeutic radiation directly to a tumor site by introducing the
micro-particles into the artery that feeds the tumor tissue.

This release contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, which are intended to be
covered by the "safe harbor" created thereby. These statements include the plans
and objectives of management for future operations, including plans and
objectives. The forward-looking statements herein are based on current
expectations that involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are
beyond control of the company. Although the company believes that the
assumptions underlying the forward-looking statements are reasonable, any one of
the assumptions could be inaccurate and, therefore, can be no assurance that the
forward-looking statements included in this release will prove to be accurate.